Blocking prokineticin receptors attenuates synovitis and joint destruction in collagen-induced arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease mediated by an interdependent network of proinflammatory molecules such as chemokines. Prokineticin 2 (PK2) is a chemokine-like peptide that modulates nociceptive threshold and immuno-inflammatory processes via two G-protein-linked receptors, prokineticin receptor 1 and 2 (PKR1 and PKR2). In the present study, we investigated the effects of the prokineticin receptor antagonist PC1 on arthritic pain and the inflammatory response in type II collagen-induced arthritis (CIA) in mice. We demonstrated that PC1, administered subcutaneously from day 25 to day 35 after CIA, improved clinical signs of arthritis such as paw edema, pain, and impaired locomotor activity. In CIA mice, PC1 was also able to lower plasma malondialdehyde (MDA) levels, suggesting a role in reducing oxidative damage, as well as joint expression levels of PK2, PKRs, TNF alpha, IL-1 beta, CD4, CD8, and NF-kB. These results suggest that blocking PKRs may be a successful strategy to control arthritic pain and pathology development.Key Messages:PK2/PKRs expression levels strongly increase in the synovium of RA mice.PC1 treatment shows anti-arthritic activity and reduces arthritis-induced pain.PC1 treatment significantly lowers synovial PK2/PKRs levels.PC1 treatment lowers plasma MDA levels and synovial levels of TNF alpha and IL -1 beta PC1 treatment is a viable therapeutic option for RA.